040-000-151 Methotrexate, CAS 59-05-2
| Synonyms | (+)-Amethopterin; (+)-4-Amino-10-methylfolic acid; N-(p-(((2,4-Diamino-6-pteridinyl)methyl)methylamino)benzoyl)-L-glutamic acid |
| Keywords | Rheumatoid arthritis, folic Acid antagonist, antineoplastic |
| Related products | Licochalcone A, Formononetin, 10-Deacetylbaccatin III, Pyrroloquinoline Quinone |
Description
Methotrexate Specifications
| Product Name | Methotrexate |
| CAS Registry Number | 59-05-2 |
| Molecular Formula | C20H22N8O5 |
| Molecular Weight | 454.44 |
| Purity | ≥99% |
| Appearance | Orange or yellow powder |
| Package | 1kg-25kg |
| Solubility | Almost insoluble in water, ethanol, chloroform or ether; soluble in dilute alkali solution, dissolved in dilute hydrochloric acid |
| Shelf life | 2 years |
| Functions | Anti-cancer, anti-Rheumatoid arthritis |
Methotrexate Description
Methotrexate was first used to fight cancer and was less toxic than other treatments. It can inhibit DNA synthesis, so it can be good medicine for cancer.
Methotrexate is a cell cycle blocker with different effects. In the late G1 / S phase, methotrexate blocks the cell cycle and therefore inhibits the synthesis of DNA, RNA, thymidine and proteins. In the past, inhibiting the enzymes involved in purine metabolism, leading to the accumulation of adenosine, or inhibiting the expression of intercellular adhesion molecules on T cells, is the main mechanism of action of methotrexate. Previous studies have observed that this compound irreversibly inhibits dihydrofolate reductase (DHFR) and thymidine synthase (TS). Methotrexate has been shown to regulate inflammation by promoting adenosine release or inhibiting the transmethylation response. In adherent splenocytes, methotrexate reduces IL-1 production.
Methotrexate Application
·Raw material of early rheumatoid drugs
·Raw materials of anti-cancer drugs
·For a variety of acute leukemia, chorionic epithelial cell carcinoma, malignant mole and psoriasis
Submit your review | |
Very pleased with Methotrexate powder.
